The first Neuraminidase inhibitor (NI) to be licensed by its manufacturer Glaxo Wellcome and SmithKline Beecham (who went on to form GSK) in 1999 was zanamivir (Relenza), an inhaled diskhaler powder. This was closely followed by oseltamivir (patented by Gilead Science and marketed by Roche) in late 1999: a capsule for oral consumption, usually three tim…
Keep reading with a 7-day free trial
Subscribe to
Trust the Evidence
to keep reading this post and get 7 days of free access to the full post archives.